Huahui Health’s Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus
Beijing-based biotech company Huahui Health, specializing in viral hepatitis, hepatology, and oncology, has announced that...
Drug
Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study
China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...
Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has...
Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China
China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...
CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...
EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment
Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...
EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases
Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...
Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review
French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...
Novo Nordisk Launches Semaglutide for Weight Management in China
Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...
Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...
Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease
Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...
Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment
Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...
Shanghai Junshi Biosciences’ Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Ascentage Pharma Submits Application for Lisaftoclax, a Novel Oral Bcl-2 Inhibitor
Ascentage Pharma (HKG: 6855) has announced that its proprietary oral Bcl-2 selective inhibitor, Lisaftoclax (APG-2575),...
Bliss Bio Secures NMPA Approval for BB-1712, Pioneering ADC Therapy
Bliss Bio announced that its Investigational New Drug (IND) application for the innovative antibody-drug conjugate...
GSK’s Blenrep Shows Survival Benefit in Phase III Multiple Myeloma Study
UK-based pharmaceutical company GSK plc (NYSE: GSK) has reported positive results from a Phase III...
Janssen-Cilag’s Nipocalimab Shows Promise in Phase II Study for Sjögren’s Disease
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), has unveiled the...